title: Effect of beclomethasone dipropionate (BDP) as extrafine aerosol on bronchoalveolar lavage (BAL) lymphocytes in chronic sarcoidosis.
abstract: OBJECTIVE
  Patients with pulmonary sarcoidosis can benefit from inhaled corticosteroids. In this study we assessed the effect of beclomethasone dipropionate (BDP), administered as extrafine, HFA(hydrofluoroalkane)-driven aerosol with high peripheral deposition, on bronchoalveolar lavage (BAL) lymphocyte numbers, as a marker of the disease.
  
  
  METHODS
  Fifteen patients with newly-diagnosed pulmonary sarcoidosis (Stages I-III) received either BDP 800 microg daily (n = 6) or placebo (n = 9) for 6 months in a parallel-group design. Before and after treatment, clinical and radiological states were assessed, bronchoalveolar lavage (BAL) performed, and the cellular composition of BAL fluid as well as cytokine production by BAL lymphocytes determined.
  
  
  RESULTS
  BDP caused a decrease in the percentage of BAL lymphocytes in the BDP (p < 0.05) but not the placebo group. HLA-DR expression on lymphocytes was diminished after BDP (p < 0.05), while intracellular cytokine production by lymphocytes was not altered. Chest radiography suggested an improvement in the BDP group. There was also a rise (p < 0.05) in the diffusing capacity for carbon monoxide.
  
  
  CONCLUSIONS
  Though based on a small group of patients, the present findings suggest that in patients with pulmonary sarcoidosis of stage II and minor functional impairment, inhalation of high doses of BDP as extrafine, peripherally deposited aerosol is associated with a reduction in the number of BAL lymphocytes, in parallel with improvements in other markers of the disease.
authors.affiliation: Pulmonary Research Institute, Germany.
authors.forename: Andrea
authors.initials: A
authors.lastname: Ludwig-Sengpiel
authors.forename: Elke
authors.initials: E
authors.lastname: Jaksztat
authors.forename: Lutz
authors.initials: L
authors.lastname: Welker
authors.forename: Thomas
authors.initials: T
authors.lastname: Zeschnigk
authors.forename: Frank
authors.initials: F
authors.lastname: Kanniess
authors.forename: Rudolf A
authors.initials: RA
authors.lastname: Jörres
authors.forename: Helgo
authors.initials: H
authors.lastname: Magnussen
authors.forename: Detlef
authors.initials: D
authors.lastname: Kirsten
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012129:Respiratory Function Tests; D017565:Sarcoidosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D000336:Aerosols; D005938:Glucocorticoids; D010919:Placebos; D001507:Beclomethasone